PFDN2

Summary

PFDN2 (prefoldin subunit 2, HGNC:8867) is a protein-coding gene on chromosome 1q23.3, encoding Prefoldin subunit 2 (Q9UHV9). Binds specifically to cytosolic chaperonin (c-CPN) and transfers target proteins to it. It is a common-essential gene (DepMap: required in 99.6% of cancer cell lines).

This gene encodes a member of the prefoldin beta subunit family. The encoded protein is one of six subunits of prefoldin, a molecular chaperone complex that binds and stabilizes newly synthesized polypeptides, thereby allowing them to fold correctly. The complex, consisting of two alpha and four beta subunits, forms a double beta barrel assembly with six protruding coiled-coils.

Source: NCBI Gene 5202 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 26 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 99.6% of screened cell lines (common-essential)
• MANE Select transcript: NM_012394

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8867
Approved symbol	PFDN2
Name	prefoldin subunit 2
Location	1q23.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000143256
Ensembl biotype	protein_coding
OMIM	613466
Entrez	5202

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000368010, ENST00000468311, ENST00000851379, ENST00000918210, ENST00000918211, ENST00000918212

RefSeq mRNA: 1 — MANE Select: NM_012394 NM_012394

CCDS: CCDS1217

Canonical transcript exons

ENST00000368010 — 4 exons

Exon	Start	End
ENSE00000958900	161102287	161102375
ENSE00000958901	161102048	161102171
ENSE00001957682	161117952	161118037
ENSE00003674485	161100561	161100859

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 98.84.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 66.9223 / max 673.2269, expressed in 1824 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
15590	66.9223	1824

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
C1 segment of cervical spinal cord	UBERON:0006469	98.84	gold quality
cortical plate	UBERON:0005343	98.57	gold quality
anterior cingulate cortex	UBERON:0009835	98.48	gold quality
cingulate cortex	UBERON:0003027	98.44	gold quality
spinal cord	UBERON:0002240	98.23	gold quality
adenohypophysis	UBERON:0002196	98.21	gold quality
ganglionic eminence	UBERON:0004023	98.18	gold quality
amygdala	UBERON:0001876	98.01	gold quality
gastrocnemius	UBERON:0001388	98.00	gold quality
prefrontal cortex	UBERON:0000451	97.99	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.95	gold quality
hypothalamus	UBERON:0001898	97.87	gold quality
putamen	UBERON:0001874	97.77	gold quality
nucleus accumbens	UBERON:0001882	97.72	gold quality
right frontal lobe	UBERON:0002810	97.72	gold quality
muscle of leg	UBERON:0001383	97.69	gold quality
caudate nucleus	UBERON:0001873	97.65	gold quality
substantia nigra	UBERON:0002038	97.65	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.56	gold quality
pituitary gland	UBERON:0000007	97.52	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	97.25	gold quality
midbrain	UBERON:0001891	97.23	gold quality
omental fat pad	UBERON:0010414	97.23	gold quality
monocyte	CL:0000576	97.22	gold quality
peritoneum	UBERON:0002358	97.22	gold quality
neocortex	UBERON:0001950	97.18	gold quality
adipose tissue of abdominal region	UBERON:0007808	97.02	gold quality
frontal cortex	UBERON:0001870	96.95	gold quality
mononuclear cell	CL:0000842	96.89	gold quality
forebrain	UBERON:0001890	96.81	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	13.80
E-MTAB-10042	yes	4.06
E-MTAB-9689	no	835.34

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

17 targeting PFDN2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6755-5P	99.95	65.59	464
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-1276	99.36	68.18	1642
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-4650-3P	99.01	68.39	1062
HSA-MIR-1233-5P	98.19	66.71	1201
HSA-MIR-6778-5P	98.19	66.59	1239
HSA-MIR-3132	97.96	67.91	711
HSA-MIR-197-5P	97.23	68.10	596
HSA-MIR-6823-5P	96.26	65.69	919
HSA-MIR-4256	96.22	67.70	669
HSA-MIR-11181-5P	96.12	67.46	665

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.6% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 3)

• Is part of an RNA polymerase II-associated complex with possible chaperone activity. (PMID:19450687)
• knockdown of PFD2 and PFD5 disrupted prefoldin formation in HTT-expressing cells, resulting in accumulation of aggregates of a pathogenic form of HTT and in induction of cell death. (PMID:23720755)
• prefoldin is amplified at 1q23.3-q24.1 in bladder cancer (PMID:23914742)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	pfdn2	ENSDARG00000025391
mus_musculus	Pfdn2	ENSMUSG00000006412
rattus_norvegicus		ENSRNOG00000083250
drosophila_melanogaster	Pfdn2	FBGN0010741
caenorhabditis_elegans		WBGENE00019220

Protein

Protein identifiers

Prefoldin subunit 2 — Q9UHV9 (reviewed: Q9UHV9)

All UniProt accessions (2): Q9UHV9, B1AQP2

UniProt curated annotations — full annotation on UniProt →

Function. Binds specifically to cytosolic chaperonin (c-CPN) and transfers target proteins to it. Binds to nascent polypeptide chain and promotes folding in an environment in which there are many competing pathways for nonnative proteins.

Subunit / interactions. Heterohexamer of two PFD-alpha type and four PFD-beta type subunits. Component of the PAQosome complex which is responsible for the biogenesis of several protein complexes and which consists of R2TP complex members RUVBL1, RUVBL2, RPAP3 and PIH1D1, URI complex members PFDN2, PFDN6, PDRG1, UXT and URI1 as well as ASDURF, POLR2E and DNAAF10/WDR92. Interacts with URI1; the interaction is phosphorylation-dependent and occurs in a growth-dependent manner.

Subcellular location. Nucleus. Cytoplasm. Mitochondrion.

Similarity. Belongs to the prefoldin subunit beta family.

RefSeq proteins (1): NP_036526* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002777	PFD_beta-like	Family
IPR009053	Prefoldin	Homologous_superfamily
IPR027235	PFD2	Family

Pfam: PF01920

UniProt features (7 total): sequence conflict 3, compositionally biased region 2, chain 1, region of interest 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
7WU7	ELECTRON MICROSCOPY	3.85
6NR8	ELECTRON MICROSCOPY	7.8
6NRD	ELECTRON MICROSCOPY	8.2
6NRC	ELECTRON MICROSCOPY	8.3
6NR9	ELECTRON MICROSCOPY	8.5
6NRB	ELECTRON MICROSCOPY	8.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UHV9-F1	81.22	0.64

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-389957	Prefoldin mediated transfer of substrate to CCT/TriC

MSigDB gene sets: 138 (showing top): STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, USF_C, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, GOBP_PROTEIN_MATURATION, GOBP_PROTEIN_STABILIZATION, USF_01, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN, GOBP_PROTEIN_FOLDING, GOBP_REGULATION_OF_PROTEIN_STABILITY, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS, DODD_NASOPHARYNGEAL_CARCINOMA_UP, USF_02, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, GOBP_REGULATION_OF_CYTOSKELETON_ORGANIZATION

GO Biological Process (4): protein folding (GO:0006457), protein stabilization (GO:0050821), positive regulation of cytoskeleton organization (GO:0051495), negative regulation of amyloid fibril formation (GO:1905907)

GO Molecular Function (4): amyloid-beta binding (GO:0001540), protein folding chaperone (GO:0044183), obsolete unfolded protein binding (GO:0051082), protein binding (GO:0005515)

GO Cellular Component (9): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), mitochondrion (GO:0005739), cytosol (GO:0005829), prefoldin complex (GO:0016272), protein folding chaperone complex (GO:0101031), RPAP3/R2TP/prefoldin-like complex (GO:1990062), protein-containing complex (GO:0032991)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
intracellular membrane-bounded organelle	2
cytoplasm	2
protein-containing complex	2
cellular process	1
protein maturation	1
regulation of protein stability	1
cytoskeleton organization	1
positive regulation of organelle organization	1
regulation of cytoskeleton organization	1
negative regulation of protein metabolic process	1
negative regulation of supramolecular fiber organization	1
regulation of amyloid fibril formation	1
amyloid fibril formation	1
peptide binding	1
molecular_function	1
protein folding	1
binding	1
nuclear lumen	1
intracellular anatomical structure	1
intracellular protein-containing complex	1
cellular_component	1

Protein interactions and networks

STRING

2042 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PFDN2	PFDN6	O15212	997
PFDN2	PDRG1	Q9NUG6	996
PFDN2	UXT	Q9UBK9	995
PFDN2	POLR2E	P19388	993
PFDN2	PFDN1	O60925	986
PFDN2	PFDN4	Q9NQP4	986
PFDN2	DNAAF10	Q96MX6	982
PFDN2	URI1	O94763	966
PFDN2	VBP1	P61758	928
PFDN2	PFDN5	Q99471	912
PFDN2	RUVBL1	P82276	903
PFDN2	ACTBL2	Q562R1	888
PFDN2	RUVBL2	Q9Y230	884
PFDN2	RPAP3	Q9H6T3	833
PFDN2	TENT4A	Q5XG87	776

IntAct

206 interactions, top by confidence:

A	B	Type	Score
VBP1	PFDN2	psi-mi:“MI:0915”(physical association)	0.870
PFDN5	PFDN2	psi-mi:“MI:0915”(physical association)	0.850
URI1	POLR2E	psi-mi:“MI:0914”(association)	0.850
CHAF1B	CBX5	psi-mi:“MI:0914”(association)	0.790
POLR2E	POLR1C	psi-mi:“MI:0914”(association)	0.770
PFDN2	PFDN1	psi-mi:“MI:0915”(physical association)	0.740
PFDN1	PFDN2	psi-mi:“MI:0915”(physical association)	0.740
PPP1CC	CCDC85C	psi-mi:“MI:0914”(association)	0.740
PPP1CC	CCDC85C	psi-mi:“MI:2364”(proximity)	0.740
PFDN2	URI1	psi-mi:“MI:0915”(physical association)	0.740
PFDN2	PDRG1	psi-mi:“MI:0915”(physical association)	0.740
PFDN4	PFDN6	psi-mi:“MI:0914”(association)	0.730
POLR2E	MED19	psi-mi:“MI:0914”(association)	0.730
L3MBTL2	E2F6	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
PFDN2	RPAP3	psi-mi:“MI:0915”(physical association)	0.710
PPP1CA	CCDC85C	psi-mi:“MI:0914”(association)	0.670
PPP1CA	CCDC85C	psi-mi:“MI:2364”(proximity)	0.670
PFDN2	POLR3A	psi-mi:“MI:0914”(association)	0.670
POLR3A	PFDN2	psi-mi:“MI:0915”(physical association)	0.670
MAPK7	PFDN6	psi-mi:“MI:0914”(association)	0.640

BioGRID (430): PFDN2 (Affinity Capture-MS), PFDN2 (Affinity Capture-MS), CD2AP (Co-fractionation), FLNA (Co-fractionation), HINT1 (Co-fractionation), NUP50 (Co-fractionation), PFDN2 (Co-fractionation), PFDN2 (Co-fractionation), PFDN2 (Co-fractionation), PFDN2 (Co-fractionation), PFDN2 (Co-fractionation), PFDN2 (Co-fractionation), PFDN2 (Co-fractionation), PFDN5 (Co-fractionation), PRKAB1 (Co-fractionation)

ESM2 similar proteins: A1A4P5, A1DGS2, A2R7Z2, B0BN18, O04350, O35685, O70591, O75347, O76031, P48427, P48428, P50502, P50503, P80584, Q07866, Q08851, Q08DB5, Q0VCY1, Q13190, Q15691, Q17QG2, Q3ZBD9, Q4SPU8, Q5D016, Q5R581, Q5R601, Q5R7N3, Q5R7Z5, Q5RF31, Q5U2U0, Q5ZLC7, Q5ZLF0, Q61166, Q63525, Q66HR2, Q66T82, Q68FJ8, Q6P848, Q6V291, Q8K1E0

Diamond homologs: A1A4P5, A8WVJ9, B0BN18, O70591, P40005, Q55GN3, Q9LJ98, Q9N5M2, Q9UHV9, Q9UTC9, Q9VTE5

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
PFDN2	“form complex”	“URI1 prefoldin co-chaperone”	binding
PFDN2	“form complex”	“Prefoldin co-chaperone”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 181 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RNA Polymerase III Chain Elongation	7	39.0×	4e-08
FGFR2 mutant receptor activation	5	33.4×	7e-06
RNA Polymerase III Transcription Termination	7	30.5×	2e-07
RNA Polymerase III Transcription Initiation From Type 2 Promoter	8	29.7×	4e-08
RNA Polymerase III Transcription Initiation From Type 1 Promoter	8	28.6×	4e-08
RNA Polymerase III Transcription Initiation From Type 3 Promoter	8	28.6×	4e-08
Activation of AMPK downstream of NMDARs	8	26.7×	6e-08
Signaling by FGFR2 IIIa TM	5	26.4×	2e-05

GO biological processes:

GO term	Partners	Fold	FDR
microtubule cytoskeleton organization	11	8.7×	2e-05
protein stabilization	16	7.0×	1e-06
mitotic cell cycle	8	7.0×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

26 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	24
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

329 predictions. Top by Δscore:

Variant	Effect	Δscore
1:161100857:TAT:T	acceptor_gain	1.0000
1:161100858:AT:A	acceptor_gain	1.0000
1:161100860:C:CC	acceptor_gain	1.0000
1:161100860:C:CG	acceptor_loss	1.0000
1:161102043:CTCA:C	donor_loss	1.0000
1:161102046:A:AC	donor_gain	1.0000
1:161102047:C:CC	donor_gain	1.0000
1:161102047:CCTG:C	donor_gain	1.0000
1:161102167:CTAGG:C	acceptor_gain	1.0000
1:161102168:TAGG:T	acceptor_gain	1.0000
1:161102169:AGG:A	acceptor_gain	1.0000
1:161102170:GG:G	acceptor_gain	1.0000
1:161102172:C:CC	acceptor_gain	1.0000
1:161102177:A:AC	acceptor_gain	1.0000
1:161102177:A:C	acceptor_gain	1.0000
1:161102282:CTCA:C	donor_loss	1.0000
1:161102283:TCA:T	donor_loss	1.0000
1:161102284:CA:C	donor_loss	1.0000
1:161102317:G:C	donor_gain	1.0000
1:161102371:ATCAC:A	acceptor_gain	1.0000
1:161102372:TCAC:T	acceptor_gain	1.0000
1:161102373:CAC:C	acceptor_gain	1.0000
1:161102373:CACC:C	acceptor_gain	1.0000
1:161102375:CCTA:C	acceptor_loss	1.0000
1:161102376:CTAA:C	acceptor_loss	1.0000
1:161102380:C:CT	acceptor_gain	1.0000
1:161102384:G:C	acceptor_gain	1.0000
1:161102384:G:GC	acceptor_gain	1.0000
1:161117949:CA:C	donor_loss	1.0000
1:161117950:A:AT	donor_loss	1.0000

AlphaMissense

997 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:161100804:A:G	L115P	1.000
1:161100825:A:G	L108P	1.000
1:161102067:A:C	L90W	1.000
1:161102088:A:T	V83D	1.000
1:161102094:C:G	R81P	1.000
1:161102103:A:G	L78P	1.000
1:161102103:A:T	L78Q	1.000
1:161102121:C:G	R72P	1.000
1:161102122:G:T	R72S	1.000
1:161102126:G:C	C70W	1.000
1:161102127:C:T	C70Y	1.000
1:161102128:A:G	C70R	1.000
1:161102133:C:G	R68P	1.000
1:161102134:G:T	R68S	1.000
1:161102154:A:G	L61P	1.000
1:161102167:C:T	V57M	1.000
1:161102169:A:G	L56P	1.000
1:161100693:A:G	L152S	0.999
1:161100777:A:C	I124S	0.999
1:161100777:A:T	I124N	0.999
1:161100792:C:G	R119P	0.999
1:161100837:A:G	L104P	0.999
1:161102066:C:A	L90F	0.999
1:161102066:C:G	L90F	0.999
1:161102067:A:G	L90S	0.999
1:161102076:A:G	L87P	0.999
1:161102103:A:C	L78R	0.999
1:161102112:C:A	G75V	0.999
1:161102112:C:T	G75E	0.999
1:161102113:C:G	G75R	0.999

dbSNP variants (sampled 300 via entrez): RS1000050394 (1:161119877 G>A), RS1000111474 (1:161109513 T>G), RS1000347712 (1:161102801 T>C), RS1000448521 (1:161108164 A>C), RS1000820564 (1:161104893 A>G,T), RS1000934890 (1:161104501 T>C), RS1001077302 (1:161115290 C>A,T), RS1001090256 (1:161107813 C>T), RS1001124523 (1:161111053 G>A), RS1001361497 (1:161114764 A>C), RS1001498301 (1:161110071 T>C), RS1001564603 (1:161111674 G>C), RS1001744696 (1:161104573 C>T), RS1001843079 (1:161116037 A>G), RS1001961229 (1:161116475 C>T)

Disease associations

OMIM: gene MIM:613466 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295976 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 3 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.00	IC50	1e+04	nM	MOLIBRESIB

PubChem BioAssay actives

1 with measured affinity, of 9 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2178542: Inhibition of PFDN2 (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	10.0000	uM

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, increases expression	3
Cyclosporine	increases expression	3
bisphenol F	affects cotreatment, increases expression	2
sodium arsenite	increases expression	2
sodium arsenate	decreases expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, increases reaction	1
methylparaben	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
dinophysistoxin 1	increases expression	1
perfluorooctane sulfonic acid	increases expression	1
perfluoro-n-nonanoic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
LDN 193189	increases expression, affects cotreatment	1
Sunitinib	increases expression	1
Leflunomide	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	affects methylation	1
Atrazine	increases expression	1
Benzo(a)pyrene	increases methylation	1
Dexamethasone	affects cotreatment, increases expression	1
Hydrogen Peroxide	increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1
Phenobarbital	affects expression	1
Silicon Dioxide	increases expression	1
Smoke	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Valproic Acid	increases expression	1

ChEMBL screening assays

8 unique, capped per target: 8 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118701	Binding	Binding affinity to PFDN2 in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E1MV	HyCyte SK-HEP-1 KO-hPFDN2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.